Regulation of ATPase II and Clearance of Cancer Cells
Regulation of ATPase II and Clearance of Cancer Cells
批准号:
6943748
负责人:
PROBAL BANERJEE
金额:
$12.95万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-05-01 至 2007-04-30
关键词:
adenosinetriphosphataseapoptosiscalcium channelcell linecell membraneenzyme activityenzyme mechanismgene expressiongenetic regulationgenetic transcriptionglycosyltransferaselaboratory mouselipid transportmicrogliamifepristoneneoplastic cellphagocytosisphosphatidylserinesprotein protein interactionsmall interfering RNAtransfection /expression vectorvoltage gated channel
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In the natural process known as phagocytosis a multicellular organism removes unwanted or injured cells with the help of scavenger cells, termed phagocytes. Such phagocytic cells, e.g. the macrophages in the peripheral system and the microglia in the brain, specifically bind to the dying cells through certain cell-surface molecules, one of which is phosphatidylserine (PS). PS, which normally resides in the inner-leaflet of the plasma membrane, flip flops to the outer leaflet in the dying cells and is recognized by PS receptors located on phagocytic cells. In healthy cells a bifunctional enzyme, which is both a Mg2+-/-ATPase and also an aminophospholipid translocase (APTL), translocates PS to the inner leaflet of the plasma membrane. This process apparently overrides the effect of two other enzymes, the scramblase (which bidirectionally translocates all phospholipids molecules) and the floppase (which very slowly translocates phospholipids from the inner leaflet to the outer). Many earlier studies have shown that offsetting the balance among APTL, scramblase, and floppase by inhibiting APTL results in externalization of PS and phagocytosis. A P-type ATPase, ATPase II, bears striking similarity in properties to APTL and transfection of antisense ATPase II cDNA causes externalization of PS. Expression of ATPase II mRNA shows tissue-specificity, with the highest levels of expression observed in the brain and the skeletal muscle. We have isolated the ATPase II promoter and showed that it displays considerable tissue specificity in luciferase reporter assays. In our current project we will further analyze the promoter of the ATPase II gene to study the sequence elements that confer this cell type-specificity of expression. Also, in our earlier studies, we had observed that stable overexpression of ATPase II causes appearance of mixed, voltage-gated calcium channels in a hippocampal neuron-derived cell line, HN2, which normally does not display any calcium current. In parallel, induced expression of the channel-forming subunit, (1B, of the N-type channels was also observed. We will prepare and test an inducible expression system for ATPase II in the HN2 cells in order to verify if this induced expression of calcium channels was due to transactivated gene expression or a protein-protein interaction between ATPase II and the calcium channel proteins. Finally, since antisense ATPase II transfection causes externalization of PS molecules, we will use this concept to design and test a novel strategy of removing cancer cells through phagocytosis without attempting to kill them with antimetabolites. In this strategy we will selectively ablate ATPase II expression in the cancer cells by using ATPase II-specific small inhibitory RNA (siRNA). Selective expression of the siRNA in cancer cells will be achieved through the use of a promoter for a highly cancer cell-selective protein, e.g. the (1-6 N acetyl glucosaminyl transferase V (GnT-V). Abrogation of ATPase II in the cancer cells would cause PS externalization and phagocytic removal of these cells. Studying the mechanism of ATPase II expression, analyzing its role in the induction of calcium channels, and evaluating its use in designing a new strategy for the removal of cancer cells will be the overall goal of our project.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Chemical Strategy of Developing Resistance-Proof, Immune-Friendly Drugs
-
批准号:10113275
-
项目类别:
-
资助金额:$41.87万
-
财政年份:2021
-
负责人:PROBAL BANERJEE
-
依托单位:
The 5-HT1A Receptor and Brain Development
-
批准号:7445477
-
项目类别:
-
资助金额:$1.08万
-
财政年份:2007
-
负责人:PROBAL BANERJEE
-
依托单位:
The 5-HT1A Receptor and Brain Development
-
批准号:7487561
-
项目类别:
-
资助金额:$23.85万
-
财政年份:2006
-
负责人:PROBAL BANERJEE
-
依托单位:
The 5-HT1A Receptor and Brain Development
-
批准号:7253430
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2006
-
负责人:PROBAL BANERJEE
-
依托单位:
The 5-HT1A Receptor and Brain Development
-
批准号:7144542
-
项目类别:
-
资助金额:$21.31万
-
财政年份:2006
-
负责人:PROBAL BANERJEE
-
依托单位:
The 5-HT1A Receptor and Brain Development
-
批准号:7120857
-
项目类别:
-
资助金额:$22.17万
-
财政年份:2005
-
负责人:PROBAL BANERJEE
-
依托单位:
Phosphatidylserine Translocase and Calcium Channels
-
批准号:6460322
-
项目类别:
-
资助金额:$3.3万
-
财政年份:1998
-
负责人:PROBAL BANERJEE
-
依托单位:
REGULATION OF APOPTOSIS BY THE SEROTONIN 1A RECEPTOR
-
批准号:2612538
-
项目类别:
-
资助金额:$7.71万
-
财政年份:1998
-
负责人:PROBAL BANERJEE
-
依托单位:
Phosphatidylserine Translocase and Calcium Channels
-
批准号:6747822
-
项目类别:
-
资助金额:$3.41万
-
财政年份:1998
-
负责人:PROBAL BANERJEE
-
依托单位:
Regulation of ATPase II and Clearance of Cancer Cells
-
批准号:6944110
-
项目类别:
-
资助金额:$7.86万
-
财政年份:1998
-
负责人:PROBAL BANERJEE
-
依托单位:
Phosphatidylserine Translocase and Calcium Channels
-
批准号:6561733
-
项目类别:
-
资助金额:$2.18万
-
财政年份:1998
-
负责人:PROBAL BANERJEE
-
依托单位:
Phosphatidylserine Translocase and Calcium Channels
-
批准号:6317030
-
项目类别:
-
资助金额:$13.45万
-
财政年份:1998
-
负责人:PROBAL BANERJEE
-
依托单位:
Phosphatidylserine Translocase and Calcium Channels
-
批准号:6561712
-
项目类别:
-
资助金额:$2.18万
-
财政年份:1998
-
负责人:PROBAL BANERJEE
-
依托单位:
Phosphatidylserine Translocase and Calcium Channels
-
批准号:6742345
-
项目类别:
-
资助金额:$1.15万
-
财政年份:1998
-
负责人:PROBAL BANERJEE
-
依托单位:
Phosphatidylserine Translocase and Calcium Channels
-
批准号:6460321
-
项目类别:
-
资助金额:$3.3万
-
财政年份:1998
-
负责人:PROBAL BANERJEE
-
依托单位:
Regulation of ATPase II and Clearance of Cancer Cells
-
批准号:6754724
-
项目类别:
-
资助金额:$23.63万
-
财政年份:1998
-
负责人:PROBAL BANERJEE
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
-
批准号:31970691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张胜萍
-
依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
-
批准号:31900527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:孙磊
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
姜黄素与TRAIL的协同抗肿瘤机制研究
-
批准号:31101223
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:曹林
-
依托单位:
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
-
批准号:81100502
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:管娜
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: